Stocktoria
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL
NYSE · XNYS · stock · Services-Commercial Physical & Biological Research · website · IPO 2000-06-23
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.0B | $4.0B | $4.1B | $4.0B | $3.5B |
| SG&A expense | $743.1M | $751.0M | $747.9M | $665.1M | $619.9M |
| Operating income | $25.2M | $227.3M | $617.3M | $651.0M | $589.9M |
| Interest expense | — | — | $136.7M | $59.3M | $73.9M |
| Income tax | $42.7M | $67.8M | $100.9M | $130.4M | $81.9M |
| Net income | -$144.3M | $22.2M | $474.6M | $486.2M | $391.0M |
| EPS (diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
| Operating cash flow | $737.6M | $734.6M | $683.9M | $619.6M | $760.8M |
| Cash & equivalents | $213.8M | $194.6M | $276.8M | $233.9M | $241.2M |
| Inventory | $299.1M | $278.5M | $380.3M | $255.8M | $199.1M |
| Total assets | $7.1B | $7.5B | $8.2B | $7.6B | $7.0B |
| Total liabilities | $3.9B | $4.0B | $4.5B | $4.6B | $4.4B |
| Shareholders' equity | $3.2B | $3.5B | $3.6B | $3.0B | $2.5B |
Source: SEC EDGAR filings · CIK 0001100682 · as of 2025-12-27. Facts from filings plus Stocktoria's own computed scores — not investment advice.